Tags

Type your tag names separated by a space and hit enter

Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Bone. 2009 May; 44(5):766-71.BONE

Abstract

INTRODUCTION

The specific pharmacological properties of bisphosphonates have raised concerns about their long-term effects on skeletal fragility that may be related to the total dose of bisphosphonate given. However, the effect of different doses on the incidence of osteoporotic fractures has not been adequately studied.

METHODS

In this retrospective analysis, we investigated the effect of different doses of intravenous pamidronate given at 3-monthly intervals on the incidence of fractures in 92 women with severe postmenopausal osteoporosis.

RESULTS

The risk of sustaining a new vertebral fracture on treatment was significantly increased by 32% for every prevalent vertebral fracture (OR: 1.32, CI: 1.05, 1.66; p=0.02). Patients with nonvertebral fractures received a significantly lower dose of pamidronate and their risk for these fractures increased by 25% for every prevalent vertebral fracture at baseline (OR: 1.25, CI: 1.01, 1.53; p=0.03). Patients who had received oral bisphosphonate before intravenous pamidronate had a significantly higher incidence of nonvertebral fractures which, however, did not hold true after adjustment for baseline BMD and prevalent fractures.

CONCLUSIONS

In patients with established osteoporosis bone fragility during treatment with intravenous pamidronate is mainly determined by the severity of the disease, assessed by the presence and numbers of prevalent fractures, rather than the dose of the bisphosphonate or the rate of bone turnover.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Makras P
Department of Endocrinology & Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Hamdy NA
No affiliation info available
Zwinderman AH
No affiliation info available
Ballieux BE
No affiliation info available
Papapoulos SE
No affiliation info available

MeSH

AgedBone DensityBone Density Conservation AgentsDiphosphonatesDrug Administration ScheduleFemaleFractures, BoneHumansOsteoporosis, PostmenopausalRetrospective Studies

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19442613

Citation

Makras, P, et al. "Bisphosphonate Dose and Incidence of Fractures in Postmenopausal Osteoporosis." Bone, vol. 44, no. 5, 2009, pp. 766-71.
Makras P, Hamdy NA, Zwinderman AH, et al. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone. 2009;44(5):766-71.
Makras, P., Hamdy, N. A., Zwinderman, A. H., Ballieux, B. E., & Papapoulos, S. E. (2009). Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone, 44(5), 766-71. https://doi.org/10.1016/j.bone.2009.01.371
Makras P, et al. Bisphosphonate Dose and Incidence of Fractures in Postmenopausal Osteoporosis. Bone. 2009;44(5):766-71. PubMed PMID: 19442613.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. AU - Makras,P, AU - Hamdy,N A T, AU - Zwinderman,A H, AU - Ballieux,B E P B, AU - Papapoulos,S E, Y1 - 2009/01/31/ PY - 2008/10/23/received PY - 2009/01/05/revised PY - 2009/01/09/accepted PY - 2009/5/16/entrez PY - 2009/5/16/pubmed PY - 2009/7/28/medline SP - 766 EP - 71 JF - Bone JO - Bone VL - 44 IS - 5 N2 - INTRODUCTION: The specific pharmacological properties of bisphosphonates have raised concerns about their long-term effects on skeletal fragility that may be related to the total dose of bisphosphonate given. However, the effect of different doses on the incidence of osteoporotic fractures has not been adequately studied. METHODS: In this retrospective analysis, we investigated the effect of different doses of intravenous pamidronate given at 3-monthly intervals on the incidence of fractures in 92 women with severe postmenopausal osteoporosis. RESULTS: The risk of sustaining a new vertebral fracture on treatment was significantly increased by 32% for every prevalent vertebral fracture (OR: 1.32, CI: 1.05, 1.66; p=0.02). Patients with nonvertebral fractures received a significantly lower dose of pamidronate and their risk for these fractures increased by 25% for every prevalent vertebral fracture at baseline (OR: 1.25, CI: 1.01, 1.53; p=0.03). Patients who had received oral bisphosphonate before intravenous pamidronate had a significantly higher incidence of nonvertebral fractures which, however, did not hold true after adjustment for baseline BMD and prevalent fractures. CONCLUSIONS: In patients with established osteoporosis bone fragility during treatment with intravenous pamidronate is mainly determined by the severity of the disease, assessed by the presence and numbers of prevalent fractures, rather than the dose of the bisphosphonate or the rate of bone turnover. SN - 1873-2763 UR - https://www.unboundmedicine.com/medline/citation/19442613/Bisphosphonate_dose_and_incidence_of_fractures_in_postmenopausal_osteoporosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(09)00400-1 DB - PRIME DP - Unbound Medicine ER -